Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Vero Group LP has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units, which means each pending matter is being handled independently in different sections of the patent office. This distribution requires the company to manage separate prosecution tracks, each with its own set of technical and procedural challenges.
PAUL C MARTIN is the busiest examiner for the company, with 1 busiest examiner pending office action. This accounts for a portion of the 2 pending office actions, with the other being handled by the other of the 2 distinct examiners. The workload is divided among the 2 distinct examiners, meaning no single examiner dominates the company's current prosecution efforts. This arrangement provides a level of diversification in the examination process.
The use of 2 distinct art units suggests that the company's pending applications involve different technical disciplines within the Biotechnology & Pharmaceuticals sector. Because there are 2 distinct examiners, the company must navigate different sets of examiner expectations. Successfully resolving the 2 pending office actions will depend on tailored responses to both examiners, including PAUL C MARTIN. The company should monitor the progress in both of the 2 distinct art units to ensure a cohesive intellectual property strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARTIN, PAUL C | 1 | 41.8% | +21.7% |
| HUMPHRIES, NICHOLAS ADAM | 1 | 34.2% | +76.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17561389 | METHOD FOR CULTIVATION OF ADHERENT CELLS IN A MULTIPARALLEL BIOREACTOR | HUMPHRIES, NICHOLAS ADAM | 30d overdue |
| 18379644 | METHOD FOR INFECTING CELLS WITH VIRUS | MARTIN, PAUL C | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18379644 | METHOD FOR INFECTING CELLS WITH VIRUS | MARTIN, PAUL C | 1653 | §103 | Final Rejection | — | Pending | Oct 12, 2023 |
| 17561389 | METHOD FOR CULTIVATION OF ADHERENT CELLS IN A MULTIPARALLEL BIOREACTOR | HUMPHRIES, NICHOLAS ADAM | 1631 | §103 | Non-Final OA | 30d overdue | Pending | Dec 23, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVero Group LP has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Paul C Martin has the most, with 1 of Vero Group LP's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
